Humana Inc: Form 10-Q for the period ended Mar 31, 2015
Filed with the SEC on Apr 29, 2015 and accepted by EDGAR at Apr 29, 2015, 16:11 ET.
Management's discussion and analysis
As filed, 68,618 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward–looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2014 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 18, 2015, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward–looking statements.
Executive Overview
General
Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. Our strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.
Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.
Business Segments
On January 1, 2015, we realigned certain of our businesses among our reportable segments to correspond with internal management reporting changes and renamed our Employer Group segment to the Group segment. Our three reportable segments remain Retail, Group, and Healthcare Services. The more significant realignments included reclassifying Medicare benefits offered to groups to the Retail segment from the Group segment, bringing all of our Medicare offerings, which are now managed collectively, together in one segment, recognizing that in some instances we market directly to individuals that are part of a group Medicare account. In addition, we realigned our military services business, primarily consisting of our TRICARE South Region contract previously included in the Other Businesses category, to our Group segment as we consider this contract with the government to be a group account. Prior period segment financial information has been recast to conform to the 2015 presentation.
We manage our business with three reportable segments: Retail, Group, and Healthcare Services. In addition, the Other Businesses category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles. These segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer to assess performance and allocate resources.
The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. In addition, the Retail segment also includes our contract with CMS to administer the LI-NET prescription drug plan program and contracts with various states to provide
Medicaid, dual eligible, and Long-Term Support Services benefits, collectively our state-based contracts. The Group segment consists of employer group commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and voluntary insurance benefits, as well as administrative services only, or ASO products. In addition, our Group segment includes our health and wellness products (primarily marketed to employer groups) and military services business, primarily our TRICARE South Region contract. The Healthcare Services segment includes services offered to our health plan members as well as to third parties, including pharmacy solutions, provider services, home based services, and clinical programs, as well as services and capabilities to advance population health. We will continue to report under the category of Other Businesses those businesses which do not align with the reportable segments described above, primarily our closed-block long-term care insurance policies.
The results of each segment are measured by income before income taxes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and home based services as well as clinical programs, to our Retail and Group customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.
Seasonality
One of the product offerings of our Retail segment is Medicare stand-alone prescription drug plans, or PDPs, under the Medicare Part D program. Our quarterly Retail segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low-income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.
Our Group segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in the Retail segment, with the Group segment’s benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. Similarly, certain of our fully-insured individual commercial medical products in our Retail segment experience seasonality in the benefit ratio akin to the Group segment, including the effect of existing previously underwritten members transitioning to policies compliant with the Health Care Reform Law with us and other carriers. As previously underwritten members transition, it results in policy lapses and the release of reserves for future policy benefits and recognition of previously deferred acquisition costs. These policy lapses generally occur during the first quarter of the new coverage year following the open enrollment period.
In addition, the Retail segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare and individual health care exchange marketing seasons.
2015 Highlights
Consolidated
- Our 2015 results reflect the continued implementation of our strategy to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and
physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. At March 31, 2015, approximately 1,456,800 members, or 54.2%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 1,301,000 members, or 53.6%, at December 31, 2014 and 1,243,500 members, or 53.4%, at March 31, 2014.
- Our pretax results for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014, were impacted by membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings, partially offset by lower favorable prior-period medical claims reserve development.
- Year-over-year comparisons of the operating cost ratio are impacted by an increase in the non-deductible health insurance industry fee mandated by the Health Care Reform Law. Likewise, year-over-year comparisons of the benefit ratio reflect the increase in this fee in the pricing of our products for 2015.
- During the three months ended March 31, 2015, we recorded a deferred tax asset of approximately $53 million, or $0.35 per diluted common share, in connection with the held-for-sale classification of Concentra Inc., or Concentra, decreasing our effective tax rate by approximately 7 percentage points. The 7 percentage point impact on our the effective tax rate was partially offset by the impact of an increase in the health insurance industry fee. We expect the sale of Concentra to close in the second quarter of 2015 and we anticipate recording a significant gain of approximately $1.00 to $1.10 per diluted common share at that time. The ultimate gain recognized will reflect considerations for costs to sell, changes in the carrying value of net assets and the related tax effect. The pending sale of Concentra is discussed below under Healthcare Services segment highlights.
- Year-over-year comparisons of diluted earnings per common share are favorably impacted by a lower number of shares used to compute diluted earnings per common share reflecting the impact of share repurchases.
- Our operating cash flow was $107 million for the three months ended March 31, 2015 compared to operating cash flow of $671 million for the three months ended March 31, 2014. The decrease in our operating cash flows for the three months ended March 31, 2015 reflects an increase in earnings more than offset by changes in the timing of working capital items primarily driven by a lower rate of growth in benefits payable commensurate with the lower 2015 membership growth.
- In September 2015, we expect to pay the federal government $882 million for the annual non-deductible health insurance industry fee compared to our payment of $562 million in 2014. This fee is not deductible for tax purposes, which significantly increased our effective income tax rate beginning in 2014. The health insurance industry fee is further described below under the section titled “Health Care Reform.”
- During the three months ended March 31, 2015, we repurchased 0.15 million shares in open market transactions for $26 million and paid dividends to stockholders of $44 million. In addition, on March 13, 2015, upon final settlement of our previously announced accelerated share repurchase agreement we received an additional 0.36 million shares as determined by the average daily volume weighted-average share price of our common stock during the term of the ASR Agreement of $146.21, bringing the total shares received under this program to 3.42 million. On March 12, 2015, we entered into a plan designed to comply with Rule 10b5-1 under the Exchange Act, pursuant to which we expect to repurchase an aggregate amount of $365 million of our common stock by June 30, 2015, to fulfill our expectation to repurchase $1 billion of our common stock under the September 2014 $2 billion authorization by that date. Our remaining repurchase authorization was $1.23 billion as of April 28, 2015 after giving effect to 0.63 million additional shares repurchased under the Rule 10b5-1 compliant plan for $112 million in April 2015.
Retail
- On April 6, 2015, CMS announced final 2016 Medicare benchmark payment rates and related technical factors impacting the bid benchmark premiums, which we refer to as the Final Rate Notice. We believe the Final Rate Notice together with the impact of payment cuts associated with the Health Care Reform Law, quality bonuses, sunset of the Star quality CMS demonstration in 2015, risk coding modifications, and other funding formula changes, indicate 2016 Medicare Advantage funding increases for us of approximately 0.8% on average. Although the overall rate adjustment is positive, geographic-specific impacts may vary from this average. Accordingly, while we believe in some markets that our members’ benefits may be adversely impacted, we believe we can effectively design Medicare Advantage products based upon the applicable level of rate changes while continuing to remain competitive compared to both the combination of original Medicare with a supplement policy as well as Medicare Advantage products offered by our competitors. Failure to execute these strategies may result in a material adverse effect on our results of operations, financial position, and cash flows.
- For the three months ended March 31, 2015, our Retail segment pretax income increased by $6 million, or 1.6% as compared to the three months ended March 31, 2014, primarily driven by the same factors impacting our consolidated results as described above.
- Individual Medicare Advantage membership of 2,685,900 at March 31, 2015 increased 258,000, or 10.6%, from 2,427,900 at December 31, 2014 and increased 355,100 members, or 15.2%, from 2,330,800 at March 31, 2014 reflecting net membership additions, particularly for our Health Maintenance Organization, or HMO, offerings for the 2015 plan year.
- Group Medicare Advantage membership of 470,900 at March 31, 2015 decreased 18,800 members, or 3.8%, from 489,700 at December 31, 2014 and decreased 6,700 members, or 1.4%, from 477,600 at March 31, 2014. The decline from December 31, 2014 primarily reflects the loss of a large group account.
- Medicare stand-alone PDP membership of 4,381,400 at March 31, 2015 increased 387,400 members, or 9.7%, from 3,994,000 at December 31, 2014 and increased 524,900 members, or 13.6%, from 3,856,500 at March 31, 2014 reflecting net membership additions, primarily for our Humana-Walmart plan offering, for the 2015 plan year.
- Our state-based Medicaid membership as of March 31, 2015 increased 22,200 members, or 7.0%, from 316,800 at December 31, 2014 and increased 209,400 members, or 161.6%, from 129,600 at March 31, 2014, in each case primarily due to the addition of members under our Florida Medicaid contract.
- Individual commercial medical membership of 1,258,100 at March 31, 2015 increased 110,000 members, or 9.6%, from 1,148,100 at December 31, 2014 and increased 424,100 members, or 50.9%, from 834,000 at March 31, 2014 primarily reflecting new sales and better retention for plans compliant with the Health Care Reform Law, both on-exchange and off-exchange. At March 31, 2015, individual commercial medical membership in plans compliant with the Health Care Reform Law, both on-exchange and off-exchange, was 944,100 members, an increase of 257,800 members, or 37.6%, from December 31, 2014 and an increase of 648,200 members, or 219.1%, from March 31, 2014.
Group Segment
- For the three months ended March 31, 2015, our Group segment pretax income increased $10 million, or 6.9% as compared to the three months ended March 31, 2014, primarily due to a decline in the operating cost ratio partially offset by an increase in the benefit ratio as discussed in the results discussion that follows.
- Membership in HumanaVitality®, our wellness and loyalty rewards program, rose 2.4% to 3,947,900 at March 31, 2015 from 3,856,800 at December 31, 2014 and rose 11.0% from 3,555,700 at March 31, 2014 primarily due to individual Medicare Advantage and fully-insured individual commercial medical membership growth.
Healthcare Services Segment
- On March 22, 2015, we signed a definitive agreement to sell our wholly-owned subsidiary Concentra to MJ Acquisition Corporation, a joint venture between Select Medical Holdings Corporation and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund, for approximately $1,055 million in cash, subject to customary adjustments. The agreement is subject to Hart-Scott-Rodino clearance and customary closing conditions, and is expected to close in the second quarter of this year.
- As discussed in the detailed Healthcare Services segment results of operations discussion that follows, our Healthcare Services segment pretax income increased $45 million, or 24.3%, for the three months ended March 31, 2015. This increase was primarily due revenue growth from our pharmacy solutions and home based services businesses as they serve our growing Medicare membership.
- Programs to enhance the quality of care for members are key elements of our integrated care delivery model. We have accelerated our process for identifying and reaching out to members in need of clinical intervention. At March 31, 2015, we had approximately 463,000 Medicare Advantage members with complex chronic conditions in the Humana Chronic Care Program, a 10.1% increase compared with approximately 420,700 Medicare Advantage members at December 31, 2014, and an increase of 55.6% compared with approximately 297,500 Medicare Advantage members at March 31, 2014. These increases reflect enhanced predictive modeling capabilities and focus on proactive clinical outreach and member engagement. We believe these initiatives lead to better health outcomes for our members and lower health care costs.
Health Care Reform
The Health Care Reform Law enacted significant reforms to various aspects of the U.S. health insurance industry. Implementation dates of the Health Care Reform Law began in September 2010 and will continue through 2018, and many aspects of the Health Care Reform Law are already effective and have been implemented by us. Certain significant provisions of the Health Care Reform Law include, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally-facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values. In addition, the Health Care Reform Law established insurance industry assessments, including an annual health insurance industry fee and a three-year $25 billion industry wide commercial reinsurance fee. The annual health insurance industry fee levied on the insurance industry was $8 billion in 2014 with increasing annual amounts thereafter, growing to $14 billion by 2017, and is not deductible for income tax purposes, which significantly increased our effective income tax rate. Our effective tax rate for the full year 2015 is expected to be approximately 46% to 47%. In 2014, we paid the federal government $562 million for the annual health insurance industry fee. We expect to pay the federal government $882 million for the annual health insurance industry fee in 2015, a 57% increase from 2014, primarily reflecting an increase in the total industry fee. In addition, statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment of the health insurance industry fee beginning in 2014. Accordingly, in addition to recording the full-year 2015 assessment in the first quarter of 2015, we are required to restrict surplus for the 2016 assessment ratably in 2015.
In addition, the Health Care Reform Law has increased and will continue to increase federal oversight of health plan premium rates and could adversely affect our ability to appropriately adjust health plan premiums on a timely basis. Financing for these reforms comes, in part, from material additional fees and taxes on us (as discussed above) and other health plans and individuals which began in 2014, as well as reductions in certain levels of payments to us and other health plans under Medicare as described in this report.
As discussed above, it is reasonably possible that the Health Care Reform Law and related regulations, as well as future legislative changes, including legislative restrictions on our ability to manage our provider network or otherwise operate our business, or regulatory restrictions on profitability, including by comparison of our Medicare Advantage profitability to our non-Medicare Advantage business profitability and a requirement that they remain within certain ranges of each other, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with the non-deductible health insurance industry fee and other assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows (including the receipt of amounts due under the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law in 2015 related to claims paid in 2014, which payments may be subject to federal administrative action). In addition, certain aspects of the Health Care Reform Law have been challenged in federal court, and we cannot predict the results of these proceedings.
We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and home based services as well as clinical programs, to our Retail and Group customers and are described in Note 14 to the condensed consolidated financial statements.
Comparison of Results of Operations for 2015 and 2014
The following discussion primarily deals with our results of operations for the three months ended March 31, 2015, or the 2015 quarter, the three months ended March 31, 2014, or the 2014 quarter.
Consolidated
(dollars in millions, except per common share results)
| Revenues: Premiums: | For the three months ended March 31, 2015 | 2014 | Change Dollars | Percentage |
|---|---|---|---|---|
| Retail | $11,578 | $9,462 | $2,116 | 22.4% |
| Group | 1,660 | 1,610 | 50 | 3.1% |
| Other Businesses | 10 | 11 | (1) | (9.1)% |
| Total premiums | 13,248 | 11,083 | 2,165 | 19.5% |
| Services: | ||||
| Retail | 4 | 14 | (10) | (71.4)% |
| Group | 169 | 193 | (24) | (12.4)% |
| Healthcare Services | 315 | 328 | (13) | (4.0)% |
| Other Businesses | 2 | 3 | (1) | (33.3)% |
| Total services | 490 | 538 | (48) | (8.9)% |
| Investment income | 95 | 91 | 4 | 4.4% |
| Total revenues | 13,833 | 11,712 | 2,121 | 18.1% |
| Operating expenses: | ||||
| Benefits | 11,005 | 9,124 | 1,881 | 20.6% |
| Operating costs | 1,945 | 1,785 | 160 | 9.0% |
| Depreciation and amortization | 93 | 82 | 11 | 13.4% |
| Total operating expenses | 13,043 | 10,991 | 2,052 | 18.7% |
| Income from operations | 790 | 721 | 69 | 9.6% |
| Interest expense | 46 | 35 | 11 | 31.4% |
| Income before income taxes | 744 | 686 | 58 | 8.5% |
| Provision for income taxes | 314 | 318 | (4) | (1.3)% |
| Net income | $430 | $368 | $62 | 16.8% |
| Diluted earnings per common share | $2.82 | $2.35 | $0.47 | 20.0% |
| Benefit ratio(a) | 83.1% | 82.3% | 0.8% | |
| Operating cost ratio(b) | 14.2% | 15.4% | (1.2)% | |
| Effective tax rate | 42.2% | 46.4% | (4.2)% |
(a) Represents total benefits expense as a percentage of premiums revenue.
(b) Represents total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income.
34
Summary
Net income was $430 million, or $2.82 per diluted common share, in the 2015 quarter compared to $368 million, or $2.35 per diluted common share, in the 2014 quarter. The 2015 quarter includes $0.35 per diluted common share, associated with a tax benefit recorded in connection with the held-for-sale classification of Concentra. Excluding the impact of the tax benefit, the increase in the 2015 quarter was primarily due to membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings. These favorable items were partially offset by lower favorable prior-period medical claims reserve development as discussed under benefits expense below. Year-over-year comparisons of diluted earnings per common share are also favorably impacted by a lower number of shares used to compute diluted earnings per common share in the 2015 quarter reflecting the impact of share repurchases.
Premiums
Consolidated premiums increased $2.2 billion, or 19.5%, from the 2014 quarter to $13.2 billion for the 2015 quarter. This increase is primarily due to an increase in Retail segment premiums mainly driven by higher average Medicare Advantage and individual commercial medical membership. Average membership is calculated by summing the ending membership for each month in a period and dividing the result by the number of months in a period. Premiums revenue reflects changes in membership and average per member premiums. Items impacting average per member premiums include changes in premium rates as well as changes in the geographic mix of membership, the mix of product offerings, and the mix of benefit plans selected by our membership.
Services revenue
Consolidated services revenue decreased $48 million, or 8.9%, from the 2014 quarter to $490 million for the 2015 quarter. This decrease is primarily due to the loss of certain large group ASO accounts as a result of continued discipline in pricing of services for self-funded accounts amid a highly competitive environment.
Investment income
Investment income totaled $95 million for the 2015 quarter compared to $91 million for the 2014 quarter as higher average invested balances were partially offset by lower interest rates.
Benefits expense
Consolidated benefits expense was $11.0 billion for the 2015 quarter, an increase of $1.9 billion, or 20.6%, from the 2014 quarter. This increase is primarily due to an increase in the Retail segment mainly driven by higher average Medicare Advantage membership and individual commercial medical membership. We experienced favorable medical claims reserve development related to prior fiscal years of $194 million in the 2015 quarter as compared to $297 million in the 2014 quarter. The decrease in favorable medical claims reserve development year-over-year primarily was due to previously implemented process changes that improved the initial accuracy of claim payment processing, as well as higher than expected flu costs in the fourth quarter of 2014.
The consolidated benefit ratio increased 80 basis points to 83.1% for the 2015 quarter compared to 82.3% for the 2014 quarter. The increase in the 2015 quarter is primarily due to an increase in the Retail and Group segment ratios as discussed below.
Operating costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs increased $160 million, or 9.0%, during the 2015 quarter compared to the 2014 quarter. This increase is primarily due to increases in costs mandated by the Health Care Reform Law, including the non-deductible health insurance industry fee, partially offset by operating cost efficiencies.
The consolidated operating cost ratio for the 2015 quarter was 14.2%, decreasing 120 basis points from the 2014 quarter. This decrease is primarily due to a decrease in the operating cost ratio in our Group segment.
Depreciation and amortization
Depreciation and amortization for the 2015 quarter totaled $93 million, compared to $82 million for the 2014 quarter, reflecting increased capital expenditures during 2014.
Interest expense
Interest expense for the 2015 quarter totaled $46 million, compared to $35 million for the 2014 quarter, reflecting a higher average long-term debt balance due to the issuance of senior notes in September 2014.
Income Taxes
Our effective tax rate during the 2015 quarter was 42.2% compared to the effective tax rate of 46.4% in the 2014 quarter. The effective tax for the three months ended March 31, 2015 includes the beneficial effect of a deferred tax asset recorded in connection with the pending sale of our Concentra subsidiary, decreasing our effective tax rate by approximately 7 percentage points, partially offset by the increase in the non-deductible health insurance industry fee.
Retail Segment
| Membership: Medical membership: | March 31, 2015 | 2014 | Change Members | Percentage |
|---|---|---|---|---|
| Individual Medicare Advantage | 2,685,900 | 2,330,800 | 355,100 | 15.2% |
| Group Medicare Advantage | 470,900 | 477,600 | (6,700) | (1.4)% |
| Medicare stand-alone PDP | 4,381,400 | 3,856,500 | 524,900 | 13.6% |
| Total Retail Medicare | 7,538,200 | 6,664,900 | 873,300 | 13.1% |
| Individual commercial (a) | 1,258,100 | 834,000 | 424,100 | 50.9% |
| State-based Medicaid | 339,000 | 129,600 | 209,400 | 161.6% |
| Total Retail medical members | 9,135,300 | 7,628,500 | 1,506,800 | 19.8% |
| Individual specialty membership (b) | 1,173,300 | 1,123,700 | 49,600 | 4.4% |
(a) Individual commercial medical membership includes Medicare Supplement members.
(b) Specialty products include dental, vision, and other supplemental health and financial protection products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.
(in millions)
| Premiums and Services Revenue: Premiums: | For the three months ended March 31, 2015 | 2014 | Change Dollars | Percentage |
|---|---|---|---|---|
| Individual Medicare Advantage | $7,433 | $6,460 | $973 | 15.1% |
| Group Medicare Advantage | 1,394 | 1,384 | 10 | 0.7% |
| Medicare stand-alone PDP | 1,003 | 865 | 138 | 16.0% |
| Total Retail Medicare | 9,830 | 8,709 | 1,121 | 12.9% |
| Individual commercial | 1,094 | 525 | 569 | 108.4% |
| State-based Medicaid | 591 | 169 | 422 | 249.7% |
| Individual specialty | 63 | 59 | 4 | 6.8% |
| Total premiums | 11,578 | 9,462 | 2,116 | 22.4% |
| Services | 4 | 14 | (10) | (71.4)% |
| Total premiums and services revenue | $11,582 | $9,476 | $2,106 | 22.2% |
| Income before income taxes | $375 | $369 | $6 | 1.6% |
| Benefit ratio | 85.8% | 85.4% | 0.4% | |
| Operating cost ratio | 10.8% | 10.7% | 0.1% |
Pretax Results
- Retail segment pretax income was $375 million in the 2015 quarter, an increase of $6 million, or 1.6%, compared to $369 million in the 2014 quarter. This increase is primarily driven by Medicare Advantage and individual commercial medical membership growth, substantially offset by an increase in the benefit ratio as discussed below.
Enrollment
- Individual Medicare Advantage membership increased 355,100 members, or 15.2%, from March 31, 2014 to March 31, 2015 reflecting net membership additions, particularly for our HMO offerings, for the 2015 plan year.
- Group Medicare Advantage membership decreased 6,700, or 1.4%, from March 31, 2014 to March 31, 2015.
- Medicare stand-alone PDP membership increased 524,900 members, or 13.6%, from March 31, 2014 to March 31, 2015 reflecting net membership additions, primarily for our Humana-Walmart plan offering, for the 2015 plan year.
- Individual commercial medical membership increased 424,100 members, or 50.9%, from March 31, 2014 to March 31, 2015 primarily reflecting new sales and better retention for plans compliant with the Health Care Reform Law, both on-exchange and off-exchange.
- State-based Medicaid membership increased 209,400 members, or 161.6%, from March 31, 2014 to March 31, 2015, primarily driven by the addition of members under our Florida Medicaid contract. State-based Medicaid membership at March 31, 2015 includes 18,400 dual-eligible demonstration members from state-based contracts.
- Individual specialty membership increased 49,600 members, or 4.4%, from March 31, 2014 to March 31, 2015, primarily driven by increased membership in dental and vision offerings.
Premiums
- Retail segment premiums increased $2.1 billion, or 22.4%, from the 2014 quarter to the 2015 quarter primarily due to membership growth across our individual Medicare Advantage, Medicare stand-alone PDP, individual commercial medical, and state-based Medicaid lines of business. Average Medicare Advantage membership increased 12.6%.
Benefits expense
- The Retail segment benefit ratio increased 40 basis points from 85.4% in the 2014 quarter to 85.8% in the 2015 quarter. The increase was primarily due to lower favorable prior-period medical claims reserve development as discussed below and higher benefit ratios associated with members from state-based contracts. These items were partially offset by the release of reserves for future policy benefits as individual commercial medical members transitioned to plans compliant with the Health Care Reform Law as well as the impact of the increase in the health insurance industry fee included in the pricing of our products.
- The Retail segment’s pretax income for the 2015 quarter included the beneficial effect of $188 million in favorable prior-period medical claims reserve development versus $277 million in the 2014 quarter. This favorable prior-period medical claims reserve development decreased the Retail segment benefit ratio by approximately 160 basis points in the 2015 quarter and approximately 290 basis points in the 2014 quarter. The year-over-year decline in favorable prior-period medical claims reserve development primarily was due to previously implemented process changes that improved the initial accuracy of claim payment processing, as well as higher than expected flu costs in the fourth quarter of 2014.
Operating costs
- The Retail segment operating cost ratio of 10.8% for the 2015 quarter increased 10 basis points from 10.7% for the 2014 quarter. This increase is primarily due to the increase in the non-deductible health insurance industry fee and the recognition of previously deferred acquisition costs as individual commercial medical members transitioned to plans compliant with the Health Care Reform Law, partially offset by scale efficiencies associated with medical membership growth in the segment. The non-deductible health insurance industry fee impacted the operating cost ratio by 170 basis points in the 2015 quarter and 120 basis points in the 2014 quarter.
Group Segment
| Membership: Medical membership: | March 31, 2015 | 2014 | Change Members | Percentage |
|---|---|---|---|---|
| Fully-insured commercial group | 1,189,600 | 1,200,200 | (10,600) | (0.9)% |
| ASO | 736,800 | 1,142,000 | (405,200) | (35.5)% |
| Military services | 3,085,600 | 3,098,000 | (12,400) | (0.4)% |
| Total group medical members | 5,012,000 | 5,440,200 | (428,200) | (7.9)% |
| Group specialty membership (a) | 6,251,200 | 6,600,900 | (349,700) | (5.3)% |
(a) Specialty products include dental, vision, and voluntary benefit products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.
(in millions)
| Premiums and Services Revenue: Premiums: | For the three months ended March 31, 2015 | 2014 | Change Dollars | Percentage |
|---|---|---|---|---|
| Fully-insured commercial group | $1,384 | $1,329 | $55 | 4.1% |
| Group specialty | 270 | 275 | (5) | (1.8)% |
| Military services | 6 | 6 | — | —% |
| Total premiums | 1,660 | 1,610 | 50 | 3.1% |
| Services | 169 | 193 | (24) | (12.4)% |
| Total premiums and services revenue | $1,829 | $1,803 | $26 | 1.4% |
| Income before income taxes | $154 | $144 | $10 | 6.9% |
| Benefit ratio | 73.9% | 72.5% | 1.4% | |
| Operating cost ratio | 24.5% | 27.1% | (2.6)% |
Pretax Results
- Group segment pretax income increased $10 million, or 6.9%, to $154 million in the 2015 quarter primarily reflecting a decline in the operating cost ratio partially offset by an increase in the benefit ratio as discussed below.
Enrollment
- Fully-insured commercial group medical membership remained relatively unchanged, decreasing 10,600 members, or 0.9%, from March 31, 2014 to March 31, 2015 as an increase in small group business membership was offset by lower membership in large group accounts.
- Group ASO commercial medical membership decreased 405,200 members, or 35.5%, from March 31, 2014 to March 31, 2015 primarily due to the loss of certain large group accounts as a result of continued discipline in pricing of services for self-funded accounts amid a highly competitive environment.
- Group specialty membership decreased 349,700 members, or 5.3%, from March 31, 2014 to March 31, 2015 primarily due to the loss of certain fully-insured group accounts.
Premiums
- Group segment premiums increased $50 million, or 3.1%, to $1.7 billion for the 2015 quarter primarily due to an increase in fully-insured commercial medical per member premiums partially offset by a net decline in fully-insured commercial medical membership.
Services
- Group segment services revenue decreased $24 million, or 12.4%, to $169 million for the 2015 quarter primarily due to a decline in group ASO commercial medical membership.
Benefits expense
- The Group segment benefit ratio increased 140 basis points from 72.5% in the 2014 quarter to 73.9% in the 2015 quarter primarily due to anticipated higher specialty drug costs and lower favorable prior-period medical
claims reserve development as discussed below, partially offset by an increase in the non-deductible health insurance industry fee included in the pricing of our products.
- The Group segment’s pretax income for the 2015 quarter included the beneficial effect of $5 million in favorable prior-period medical claims reserve development versus $20 million in the 2014 quarter. This favorable prior-period medical claims reserve development decreased the Group segment benefit ratio by approximately 30 basis points in the 2015 quarter versus approximately 120 basis points in the 2014 quarter. The year-over-year decline in favorable prior-period medical claims reserve development primarily was due to a relatively small number of higher severity claims in the 2015 quarter associated with prior periods.
Operating costs
- The Group segment operating cost ratio of 24.5% for the 2015 quarter decreased 260 basis points from 27.1% for the 2014 quarter. The decrease primarily reflects a decline in our group ASO commercial medical membership which carries a higher operating cost ratio than our fully-insured commercial medical membership, as well as operating cost efficiencies associated with our fully-insured business as a result of our cost reduction initiatives. These decreases were partially offset by the impact of an increase in the non-deductible health insurance industry fee. The non-deductible health insurance industry fee impacted the operating cost ratio by 140 basis points in the 2015 quarter and 100 basis points in the 2014 quarter.
Healthcare Services Segment
(in millions)
| Revenues: Services: | For the three months ended March 31, 2015 | 2014 | Change Dollars | Percentage |
|---|---|---|---|---|
| Provider services | $279 | $284 | $(5) | (1.8)% |
| Home based services | 29 | 23 | 6 | 26.1% |
| Pharmacy solutions | 7 | 21 | (14) | (66.7)% |
| Total services revenues | 315 | 328 | (13) | (4.0)% |
| Intersegment revenues: | ||||
| Pharmacy solutions | 4,960 | 3,857 | 1,103 | 28.6% |
| Provider services | 364 | 302 | 62 | 20.5% |
| Home based services | 190 | 118 | 72 | 61.0% |
| Clinical programs | 49 | 50 | (1) | (2.0)% |
| Total intersegment revenues | 5,563 | 4,327 | 1,236 | 28.6% |
| Total services and intersegment revenues | $5,878 | $4,655 | $1,223 | 26.3% |
| Income before income taxes | $230 | $185 | $45 | 24.3% |
| Operating cost ratio | 95.4% | 95.3% | 0.1% |
Pretax results
- Healthcare Services segment pretax income of $230 million for the 2015 quarter increased $45 million, or 24.3%, from the 2014 quarter primarily due to revenue growth from our pharmacy solutions and home based services businesses as they serve our growing Medicare membership.
Script Volume
- Humana Pharmacy Solutions® script volumes for Retail and Group segment membership increased to approximately 96 million in the 2015 quarter, up 22% versus scripts of approximately 79 million in the 2014 quarter. This increase primarily reflects growth associated with higher average medical membership for the 2015 quarter than in the 2014 quarter.
Intersegment revenues
- Intersegment revenues increased $1.2 billion, or 28.6%, from the 2014 quarter to $5.6 billion for the 2015 quarter primarily due to growth in our Medicare membership which resulted in higher utilization of our pharmacy solutions and home based services businesses.
Operating costs
- The Healthcare Services segment operating cost ratio of 95.4% for the 2015 quarter was relatively unchanged from the 2014 quarter.
Liquidity
Our primary sources of cash include receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, borrowings, and proceeds from sales of businesses. Our primary uses of cash include disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including taxes and assessments. The use of operating cash flows may be limited by regulatory requirements which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by Departments of Insurance.
The effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law are impacting the timing of our operating cash flows, as we built receivables for the 2014 coverage year that we expect to collect in the second half of 2015 and we are building receivables for the 2015 coverage year that we expect to collect in the second half of 2016. The net receivable balance associated with the 3Rs was approximately $732 million at March 31, 2015, including $668 million related to the 2014 coverage year, and $679 million at December 31, 2014. Any amounts receivable or payable associated with these risk limiting programs may have an impact on subsidiary liquidity, with any temporary shortfalls funded by the parent company.
For additional information on our liquidity risk, please refer to the section entitled “Risk Factors” in our 2014 Form 10-K.
Cash and cash equivalents remained relatively unchanged at approximately $1.9 billion at March 31, 2015 and December 31, 2014. The change in cash and cash equivalents for the three months ended March 31, 2015 and 2014 is summarized as follows:
(in millions)
| 2015 | 2014 | |
|---|---|---|
| Net cash provided by operating activities | $107 | $671 |
| Net cash used in investing activities | (94) | (171) |
| Net cash (used in) provided by financing activities | (2) | 24 |
| Increase in cash and cash equivalents | $11 | $524 |
41
Cash Flow from Operating Activities
The decrease in operating cash flows from the 2014 quarter to the 2015 quarter primarily results from an increase in earnings more than offset by changes in the timing of working capital items primarily driven by a lower rate of growth in benefits payable commensurate with the lower 2015 membership growth, significant pharmacy growth including receivables for manufacturer rebates, and the timing of receipts for premiums.
The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. We illustrate these changes with the following summaries of benefits payable and receivables.
The detail of benefits payable was as follows at March 31, 2015 and December 31, 2014:
(in millions)
| March 31, 2015 | December 31, 2014 | 2015 Quarter Change | 2014 Quarter Change | |
|---|---|---|---|---|
| IBNR (1) | $3,398 | $3,254 | $144 | $354 |
| Reported claims in process (2) | 553 | 475 | 78 | 164 |
| Other benefits payable (3) | 813 | 746 | 67 | 21 |
| Total benefits payable | $4,764 | $4,475 | $289 | $539 |
(1) IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i.e. a shorter time span results in a lower IBNR).
(2) Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.
(3) Other benefits payable primarily include amounts owed to providers under capitated and risk sharing arrangements.
The increase in benefits payable from December 31, 2014 to March 31, 2015 and from December 31, 2013 to March 31, 2014 largely was due to an increase in IBNR, primarily as a result of Medicare Advantage and individual commercial medical membership growth, and an increase in the amount of processed but unpaid claims, including amounts due to our pharmacy benefit administrator, which fluctuate due to month-end cutoff. The 2015 quarter change in IBNR was $144 million as compared to the 2014 quarter change in IBNR of $354 million primarily reflecting the impact of enrollment changes in each quarterly period. As discussed previously, our cash flows are impacted by changes in enrollment. Membership growth in new fully-insured individual commercial medical plans compliant with the Healthcare Reform Law as well as growth in individual Medicare Advantage membership in the 2014 quarter (the first period plans compliant with the Health Care Reform Law were effective) outpaced membership growth in these plans in the 2015 quarter. In addition, growth in group Medicare Advantage membership in the 2014 quarter favorably impacted the 2014 quarter change while a decline in group Medicare Advantage membership in the 2015 quarter negatively impacted the 2015 quarter change.
The detail of total net receivables was as follows at March 31, 2015 and December 31, 2014:
(in millions)
| March 31, 2015 | December 31, 2014 | 2015 Quarter Change | 2014 Quarter Change | |
|---|---|---|---|---|
| Medicare | $1,206 | $664 | $542 | $523 |
| Commercial and other | 523 | 382 | 141 | (24) |
| Military services | 72 | 106 | (34) | 11 |
| Allowance for doubtful accounts | (111) | (99) | (12) | — |
| Total net receivables | $1,690 | $1,053 | 637 | 510 |
| Reconciliation to cash flow statement: | ||||
| Receivables held-for-sale and disposition of receivables from sale of business | 7 | 14 | ||
| Change in receivables per cash flow statement resulting in cash from operations | $644 | $524 |
The changes in Medicare receivables for both the 2015 quarter and 2014 quarter reflect the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the final and mid-year settlements with CMS in July and August, respectively.
The increase in commercial and other receivables primarily relates to growth in our individual commercial medical membership.
Many provisions of the Health Care Reform Law became effective in 2014, including the commercial risk adjustment, risk corridor, and reinsurance provisions as well as the non-deductible health insurance industry fee. As discussed previously, the timing of payments and receipts associated with these provisions are impacting our operating cash flows as we built a receivable for the 2014 coverage year that we expect to collect in the second half of 2015 and as we build a receivable for the 2015 coverage year that we expect to collect in the second half of 2016. The net receivable balance associated with the 3Rs was approximately $732 million at March 31, 2015 and $679 million at December 31, 2014, including certain amounts recorded in receivables as noted above. In September 2015, we expect to pay the federal government $882 million for the annual health insurance industry fee.
Cash Flow from Investing Activities
Proceeds from sales and maturities of investment securities exceeded purchases by $29 million in the 2015 quarter. During the 2014 quarter, we reinvested a portion of our operating cash flows in investment securities, primarily investment-grade fixed income securities, totaling $131 million.
Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were $123 million in the 2015 quarter and $106 million in the 2014 quarter reflecting increased spending associated with growth in our provider services and pharmacy businesses in our Healthcare Services segment. Excluding acquisitions, we expect total capital expenditures in 2015 in a range of approximately $525 million to $575 million compared to total capital expenditures of $528 million for full year 2014.
Cash Flow from Financing Activities
Receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claims payments by $128 million during the 2015 quarter and $239 million during the 2014 quarter. Our net receivable for CMS subsidies and brand name prescription drug discounts was $1.5 billion at March 31, 2015 compared to $474 million at March 31, 2014 and $1.7 billion at December 31, 2014. Refer to Note 6 to the condensed consolidated financial statements.
Under our administrative services only TRICARE South Region contract, health care cost payments for which we do not assume risk exceeded reimbursements from the federal government by $28 million during the 2015 quarter compared to $23 million during the 2014 quarter.
Receipts from HHS associated with cost sharing provisions of the Health Care Reform Law for which we do not assume risk were $23 million higher than claims payments during the 2015 quarter and $4 million higher than claims payments during the 2014 quarter.
We repurchased 0.1 million shares for $26 million in the 2015 quarter and 0.1 million shares for $11 million in the 2014 quarter under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for an aggregate cost of $40 million in the 2015 quarter and $38 million in the 2015 quarter.
We paid dividends to stockholders of $44 million during both the 2015 quarter and the 2014 quarter, as discussed further below.
Future Sources and Uses of Liquidity
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights, in 2014 and 2015 under our Board approved quarterly cash dividend policy:
(in millions)
| Record Date 2014 payments | Payment Date | Amount per Share | Total Amount |
|---|---|---|---|
| 12/31/2013 | 1/31/2014 | $0.27 | $42 |
| 3/31/2014 | 4/25/2014 | $0.27 | $42 |
| 6/30/2014 | 7/25/2014 | $0.28 | $43 |
| 9/30/2014 | 10/31/2014 | $0.28 | $43 |
| 2015 payments | |||
| 12/31/2014 | 1/30/2015 | $0.28 | $42 |
| 3/31/2015 | 4/24/2015 | $0.28 | $42 |
In April 2015, our Board declared a cash dividend of $0.29 per share payable on July 31, 2015 to stockholders of record on June 30, 2015. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.
Stock Repurchases
In September 2014, our Board of Directors replaced a previous share repurchase authorization of up to $1 billion (of which $816 million remained unused) with a new authorization for repurchases of up to $2 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on December 31, 2016. Under the new share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing.
On November 7, 2014, we announced that we had entered into an accelerated share repurchase agreement, or ASR Agreement, with Goldman, Sachs & Co., or Goldman Sachs, to repurchase $500 million of our common stock as part of the $2 billion share repurchase program authorized in September 2014. Under the ASR Agreement, on November
10, 2014, we made a payment of $500 million to Goldman Sachs from available cash on hand and received an initial delivery of 3.06 million shares of our common stock from Goldman Sachs based on the then current market price of Humana common stock. The payment to Goldman Sachs was recorded as a reduction to stockholders’ equity, consisting of a $400 million increase in treasury stock, which reflected the value of the initial 3.06 million shares received upon initial settlement, and a $100 million decrease in capital in excess of par value, which reflected the value of stock held back by Goldman Sachs pending final settlement of the ASR Agreement. Upon settlement of the ASR on March 13, 2015, we received an additional 0.36 million shares as determined by the average daily volume weighted-average share price of our common stock during the term of the ASR Agreement of $146.21, bringing the total shares received under this program to 3.42 million. In addition, upon settlement we reclassified the $100 million value of stock initially held back by Goldman Sachs from capital in excess of par value to treasury stock.
Excluding the 0.36 million shares received in March 2015 upon settlement of our ASR Agreement for which no cash was paid during the period, share repurchases were as follows during the three months ended March 31, 2015 and 2014:
(in millions)
| Authorization Date | Purchase Not to Exceed | Three months ended March 31, 2015 Shares | Cost | 2014 Shares | Cost |
|---|---|---|---|---|---|
| September 2014 | $2,000 | 0.15 | $26 | — | $— |
| April 2014 | 1,000 | — | — | — | — |
| April 2013 | 1,000 | — | — | 0.10 | 11 |
| Total repurchases | 0.15 | $26 | 0.10 | $11 |
Our remaining repurchase authorization was $1.23 billion as of April 28, 2015 after giving effect to 0.63 million additional shares repurchased under a Rule 10b5-1 compliant plan for $112 million in April 2015.
In connection with employee stock plans, we acquired 0.2 million common shares for $40 million and 0.4 million common shares for $38 million during the three months ended March 31, 2015 and 2014, respectively, which amounts are not included in the table above.
Treasury Stock Reissuance
We reissued 0.7 million shares of treasury stock during the three months ended March 31, 2015 at a cost of $39 million associated with restricted stock unit vestings and option exercises.
Senior Notes
In September 2014, we issued $400 million of 2.625% senior notes due October 1, 2019, $600 million of 3.85% senior notes due October 1, 2024 and $750 million of 4.95% senior notes due October 1, 2044. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses, were $1.73 billion. We used a portion of the net proceeds to redeem the 6.45% senior unsecured notes as discussed below. We previously issued $500 million of 6.45% senior notes due June 1, 2016, $500 million of 7.20% senior notes due June 15, 2018, $300 million of 6.30% senior notes due August 1, 2018, $600 million of 3.15% senior notes due December 1, 2022, $250 million of 8.15% senior notes due June 15, 2038, and $400 million of 4.625% senior notes due December 1, 2042.
Our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The 7.20% and 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes (other than the 6.30% senior notes) contain a change of control provision that may require us to purchase the notes under certain circumstances.
In October 2014, we redeemed the $500 million 6.45% senior unsecured notes due June 1, 2016, at 100% of the principal amount plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling approximately $560 million. We recognized a loss on extinguishment of debt of approximately $37 million in October 2014 for the redemption of these notes.
Credit Agreement
Our 5-year $1.0 billion unsecured revolving credit agreement expires July 2018. Under the credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The LIBOR spread, currently 110 basis points, varies depending on our credit ratings ranging from 90.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15 basis points, may fluctuate between 10.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.
The terms of the credit agreement include standard provisions related to conditions of borrowing, including a customary material adverse effect clause which could limit our ability to borrow additional funds. In addition, the credit agreement contains customary restrictive and financial covenants as well as customary events of default, including financial covenants regarding the maintenance of a minimum level of net worth of $8.1 billion at March 31, 2015 and a maximum leverage ratio of 3.0:1. We are in compliance with the financial covenants, with actual net worth of $10.0 billion and an actual leverage ratio of 1.3:1, as measured in accordance with the credit agreement as of March 31, 2015. In addition, the credit agreement includes an uncommitted $250 million incremental loan facility.
At March 31, 2015, we had no borrowings outstanding under the credit agreement and we had outstanding letters of credit of $4 million secured under the credit agreement. No amounts have been drawn on these letters of credit. Accordingly, as of March 31, 2015, we had $996 million of remaining borrowing capacity under the credit agreement, none of which would be restricted by our financial covenant compliance requirement. We have other customary, arms-length relationships, including financial advisory and banking, with some parties to the credit agreement.
Commercial Paper
In October 2014, we entered into a commercial paper program pursuant to which we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time, with the aggregate face or principal amount outstanding under the program at any time not to exceed $1 billion. The net proceeds of issuances have been and are expected to be used for general corporate purposes, including to repurchase shares of our common stock. The maximum principal amount outstanding at any one time during the three months ended March 31, 2015 was $75 million. There were no outstanding borrowings at March 31, 2015 or December 31, 2014.
Liquidity Requirements
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares. In addition, we anticipate gross proceeds of $1,055 million, excluding selling costs, from the sale of Concentra which is expected to close in the second quarter of 2015.
Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at March 31, 2015 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa3 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $750 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $2 million, up to a maximum 100 basis points, or annual interest expense by $8 million.
In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were $1.2 billion at March 31, 2015 compared to $1.4 billion at December 31, 2014, primarily reflecting capital expenditures, common stock repurchases, and payment of shareholder dividends. As described in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations under the section titled “Health Care Reform,” statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment. Therefore, in addition to recording the full-year 2015 assessment in the first quarter of 2015, we are required to restrict surplus for the 2016 assessment ratably in 2015. In September 2015, we expect to pay the federal government $882 million for the annual health insurance industry fee.
Regulatory Requirements
Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.
Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of December 31, 2014, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately $6.0 billion, which exceeded aggregate minimum regulatory requirements of $4.1 billion. The amount of dividends that we expect to be paid to our parent company in 2015 is approximately $940 million in the aggregate. However, subsidiary dividends are subject to state regulatory approval, the amount and timing of which could be reduced or delayed. This compares to dividends that were paid to our parent company for the full year 2014 of approximately $927 million.
Market risk
As filed, 2,053 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.
Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA- at March 31, 2015. Our net unrealized position increased $47 million from a net unrealized gain position of $475 million at December 31, 2014 to a net unrealized gain position of $522 million at March 31, 2015. At March 31, 2015, we had gross unrealized losses of $31 million on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. There were no material other-than-temporary impairments during the three months ended March 31, 2015. While we believe that these impairments are temporary and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or other-than-temporary impairments may be recorded in future periods.Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 4.2 years as of March 31, 2015 and 4.1 years as of December 31, 2014. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately $471 million.
Controls and procedures
As filed, 1,293 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended March 31, 2015.
Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes in the Company’s internal control over financial reporting during the quarter ended March 31, 2015 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-01-01 to 2015-03-31 | $13.83bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2015-01-01 to 2015-03-31 | $1.95bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2015-01-01 to 2015-03-31 | $790.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-01-01 to 2015-03-31 | $46.0m | us-gaap:InterestExpense |
| Income tax | 3 months2015-01-01 to 2015-03-31 | $314.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-01-01 to 2015-03-31 | $430.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-01-01 to 2015-03-31 | $2.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-01-01 to 2015-03-31 | $2.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-01-01 to 2015-03-31 | 152,349,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2015-01-01 to 2015-03-31 | $107.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2015-01-01 to 2015-03-31 | $123.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2015-01-01 to 2015-03-31 | $44.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2015-01-01 to 2015-03-31 | $66.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2015-03-31 | $1.95bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-03-31 | $17.40bn | us-gaap:AssetsCurrent |
| Total assets | At period end2015-03-31 | $25.62bn | us-gaap:Assets |
| Current liabilities | At period end2015-03-31 | $9.18bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-03-31 | $15.58bn | us-gaap:Liabilities |
| Long-term debt | At period end2015-03-31 | $3.82bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2015-03-31 | $10.04bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2015-03-31 | 149,781,272 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-15-000061. Last ingested by Listed: Nov 13, 2026, 14:11 ET. Listed shows no prices and gives no investment advice.